I

HTA ID	Drug	Brand	Indication	Assessment status	Date
-	Ibrutinib	Imbruvica®	For the treatment of patients with chronic lymphocytic leukaemia who have received ≥1 prior therapy, or as a first-line treatment in the presence of del(17p) or TP53 mutation in patients not suitable for chemoimmunotherapy.	Assessment process complete	1st October 2015
-	Ibrutinib	Imbruvica®	For the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL).	Assessment process complete	6th October 2015
-	Ibrutinib	Imbruvica®	For the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). This indication is an extension to the original licence in the relapsed/refractory setting.	Rapid Review Complete	24th August 2016
20032	Ibrutinib	Imbruvica®	As a single agent or in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).	Rapid Review Complete	4th August 2020
22054	Ibrutinib	Imbruvica®	In combination with venetoclax for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.	Full HTA submission received from Applicant	14th February 2023
-	Icatibant	Firazyr®	For symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (type I and II HAE).	Rapid Review Complete	31st July 2013
23006	Icosapent ethyl	Vazkepa®	Icosapent ethyl (Vazkepa®) is indicated to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (?150 mg/dL [?1.7 mmol/L] and established cardiovascular disease, or diabetes, and at least one other cardiovascular risk factor.	Pre submission consultation scheduled	28th March 2023
-	Idarucizumab	Praxbind®	As a specific reversal agent for dabigatran in adult patients treated with Pradaxa (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required: for emergency surgery/urgent procedures or life-threatening or uncontrolled bleeding.	Rapid Review Complete	18th December 2015
-	Idebenone	Raxone®	For the treatment of visual impairment in adolescent and adult patients with Leber’s Hereditary Optic Neuropathy (LHON).	Assessment process complete	30th August 2018
-	Idelalisib	Zydelig®	In combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.	Assessment process complete	16th February 2016
20040	Imipenem/cilastatin/relebactam	Recarbrio®	For the treatment of infections due to aerobic gram-negative organisms in adults with limited treatment options.	Rapid Review Complete	21st October 2020
-	Imiquimod 3.75%	Zyclara®	For topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis (AK) of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.	Rapid Review Complete	19th September 2013
20051	Inclisiran	Leqvio®	For the treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia in adult patients, as an adjunct to diet (a) in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach low density lipoprotein cholesterol (LDL-C) goals with the maximum tolerated dose of a statin or (b) alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.	Assessment process complete	23rd March 2022
-	Incobotulinum Toxin Type A	Xeomin®	For the symptomatic treatment of blepharospasm, cervical dystonia of a predominantly rotational form (spasmodic torticollis) and of post-stroke spasticity of the upper limb presenting with flexed wrist and clenched fist in adults.	Rapid Review Complete	6th March 2014
-	Indacaterol	Onbrez®	For the treatment of COPD.	Rapid Review Complete	15th January 2010
20023	Indacterol/glycopyrronium/mometasone furoate	Enerzair®	As a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting β2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.	Rapid Review Complete	10th June 2020
20024	Indacterol/mometasone furoate	Atectura®	As maintenance treatment of asthma in adults and adolescents 12 years and older not adequately controlled with inhaled corticosteroids and inhaled short acting β2 agonists.	Rapid Review Complete	10th June 2020
-	Infliximab	Inflectra®	For the treatment of Rheumatoid Arthritis, Adult Crohn’s disease, Paediatric Crohn’s disease, Ulcerative Colitis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis.	Rapid Review Complete	24th September 2013
20012	Infliximab	Remsima SC®	In combination with methotrexate, is indicated in rheumatoid arthritis for the reduction of signs and symptoms as well as the improvement in physical function in: adult patients with active disease when the response to disease modifying antirheumatic drugs (DMARDs), including methotrexate, has been inadequate; adult patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs.	Rapid Review Complete	24th March 2020
20042	Infliximab	Remsima® SC	For treatment of adult patients with Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis in line with the adult indications of the IV formulation.	Rapid Review Complete	15th October 2020
-	Ingenol mebutate	Picato®	For cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (AK) in adults.	Rapid Review Complete	6th December 2012
-	Inhaled insulin	Exubera®	Pfizer submitted a report on the clinical and cost effectiveness of inhaled insulin (Exubera®) versus sub-cutaneous insulin in patients with diabetes mellitus in support of their application for reimbursement under the Community Drug Schemes.	Assessment process complete	13th July 2006
19034	Inotersen	Tegsedi®	For the treatment of Stage 1 or Stage 2 polyneuropathy in adult patients with hereditary transthyretin (TTR) amyloidosis (hATTR).	Assessment process complete	11th February 2022
-	Inotuzumab ozogamicin	Besponsa®	As monotherapy for the treatment of adults with relapsed or refractory (R/R) CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).	Assessment process complete	14th September 2018
-	Insulin aspart	Fiasp®	For the treatment of diabetes mellitus in adults.	Rapid Review Complete	14th June 2017
-	Insulin aspart	NovoRapid® FlexTouch ®	For the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.	Rapid Review Complete	28th August 2014
-	Insulin Degludec	Tresiba®	Treatment of diabetes mellitus	Assessment process complete	6th May 2015
-	Insulin degludec/liraglutide (IDegLira)	Xultophy®	For the treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or in combination with a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) or basal insulin does not provide adequate glycaemic control.	Rapid Review Complete	18th October 2016
-	Insulin Glargine	Abasaglar®	For the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.	Rapid Review Complete	12th October 2015
-	Insulin Glargine U300	Toujeo®	for the treatment of diabetes mellitus in adults.	Rapid Review Complete	2nd July 2015
-	Ipilimumab	Yervoy®	For the treatment of advanced (unresectable or metastatic) melanoma in adult patients who have received prior therapy.	Assessment process complete	6th September 2011
-	Iron (III) isomaltoside 1000	Diafer®	For the treatment of iron deficiency in patients with chronic kidney disease on dialysis, when oral iron preparations are ineffective or cannot be used.	Rapid Review Complete	20th November 2015
-	Iron (III) isomaltoside 1000	Monover®	For the treatment of Iron deficiency anaemia when oral iron preparations are ineffective or cannot be used or where there is a clinical need to deliver iron rapidly.	Rapid Review Complete	20th November 2015
-	Iron isomaltoside 1000	MonoVer®	For the treatment of iron deficiency anaemia in the following circumstances: When oral iron preparations are ineffective or cannot be used and where there is a clinical need to deliver iron rapidly.	Rapid Review Complete	2nd February 2011
23024	Isatuximab	Sarclisa®	Isatuximab (Sarclisa®) in combination with carfilzomib and dexamethasone, is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.	Rapid Review Complete	25th May 2023
-	Isavuconazole	Cresemba®	For the treatment of invasive aspergillosis	Rapid Review Complete	11th May 2016
-	Isavuconazole	Cresemba®	For the treatment of mucormycosis in adult patients for whom amphotericin B is inappropriate.	Rapid Review Complete	11th May 2016
20027	IUB™ Ballerine®	IUB™ Ballerine® MIDI 15mm diameter SCU300B	For intrauterine contraception for up to five years.	Rapid Review Complete	29th July 2020
20062	IUB™ Ballerine®	IUB™ Ballerine® MIDI 15mm diameter SCU300B	For intrauterine contraception for up to five years.	Rapid Review Complete	17th February 2021
-	Ivacaftor	Kalydeco®	For the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation	Assessment process complete	1st February 2013
-	Ivacaftor	Kalydeco®	For the treatment of children with CF aged 2 years and older and weighing less than 25 kg who have one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R.	Assessment process complete	12th October 2016
-	Ivacaftor	Kalydeco®	For the treatment of patients with cystic fibrosis aged 18 years and older who have the R117H mutation in the CFTR gene.	Assessment process complete	5th January 2017
22022	Ivacaftor/tezacaftor/elexacaftor	Kaftrio®	Ivacaftor/tezacaftor/elexacaftor (Kaftrio®) in combination with ivacaftor for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.	Assessment Process Complete	9th February 2023
23015	Ivosidenib	Tibsovo®	To be used in combination with azacitidine, as indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.	Rapid Review Complete	17th April 2023
23016	Ivosidenib	Tibsovo®	For the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R 132 mutation who were previously treated by at least one prior line of systemic therapy	Rapid Review Complete	17th April 2023
-	Ixazomib	Ninlaro®	In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.	Assessment process complete	18th December 2017
-	Ixekizumab	Taltz®	For the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.	Rapid Review Complete	26th July 2016
-	Ixekizumab	Taltz®	For the treatment of active PsA in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies	Rapid Review Complete	20th November 2018